Sandu Pharmaceuticals Limited is a prominent Indian healthcare entity dedicated to the **manufacturing and trading of Ayurvedic medicines** under the venerable **SANDU** brand. The company operates within a single specialized business segment: **Ayurvedic Property Medicines**. By bridging the gap between traditional Ayurvedic wisdom and modern scientific validation, the company has established a resilient market presence characterized by high customer loyalty and **inelastic demand** for its core products. The company is strategically positioned to capitalize on the **National Ayush Mission** and the structural consumer shift toward natural wellness solutions. To maintain its competitive edge against the disorganized sector, Sandu emphasizes **superior product efficacy** and stringent adherence to globally recognized quality standards, including **ISO 9001:2015** and **Good Manufacturing Practices (GMP)**. --- ### **Product Portfolio & Therapeutic Focus** The company’s product strategy focuses on transitioning traditional remedies into **contemporary formats** that meet modern consumer needs. * **Respiratory Care (Flagship Segment):** A dominant category led by **Vasa Ayurvedic Cough Syrup**. This product utilizes a **2X Power** formulation of **Adulsa** and **Tulasi**. Key therapeutic ingredients include: * **Tulasi:** Provides anti-viral and anti-inflammatory benefits. * **Shunthi:** Acts as an anti-microbial and bronchodilator. * **Yashtimadhu:** Liquefies phlegm and soothes mucosa. * **Pippali:** Functions as a **bioenhancer** to improve the bioavailability of other ingredients. * **Research & Development (R&D):** Ongoing initiatives are focused on expanding the herbal platform through **New Product Development (NPD)** to diversify the product basket. * **International Expansion:** The company is aggressively scaling its global footprint through participation in **Exports Industry Trade Shows**, with recent international forays beginning to contribute to the top line. --- ### **Manufacturing Infrastructure & Operational Model** Sandu Pharmaceuticals utilizes a centralized operational structure designed for scalability and quality control. * **Primary Facility:** Located in the **Pilerne Industrial Estate, Goa**. * **Corporate Headquarters:** Situated in **Chembur, Mumbai**. * **Strategic Supply Chain:** The company maintains a specialized arrangement with **Sandu Brothers Private Limited**, which handles the manufacturing, processing, and packing of drugs according to Sandu Pharmaceuticals' proprietary specifications. * **Asset Management:** In November 2023, the company successfully regained possession of **Plot Nos 114/5 (735 sq. meters)** in Goa following the revocation of a previous cancellation order, securing vital space for future expansion. --- ### **Corporate Structure & Related Party Framework** As of **August 10, 2024**, Sandu Pharmaceuticals transitioned to a **standalone entity** following the divestment of its only subsidiary to streamline operations. | Feature | Detail | | :--- | :--- | | **Subsidiary Status** | **None** (Sandu Phytoceuticals Pvt Ltd sold in May 2024 for **₹66,700**) | | **Reporting Basis** | Standalone (Consolidated reporting ceased as of **Q3 FY25**) | | **Trademark Licensing** | Operates under licenses from **Sandu Brothers Private Limited** | | **RPT Purchase/Sale Limit** | Up to **₹100 Crores** per annum (valid until Sept 2029) | | **Royalty Cap** | Up to **₹5 Crores** per annum for brand usage | --- ### **Financial Performance & Capital Allocation** The company maintains a stable financial profile with consistent shareholder returns despite macroeconomic headwinds. **Consolidated Financial Summary** *(Figures in **₹ Lakhs**)* | Metric | FY 2024-25 | FY 2023-24 | Growth (Y-o-Y) | | :--- | :--- | :--- | :--- | | **Income from Operations** | **6,719.24** | **6,728.07** | **(0.13%)** | | **Profit Before Tax (PBT)** | **215.85** | **207.24** | **4.15%** | | **Profit After Tax (PAT)** | **155.17** | **146.07** | **6.23%** | **Capital Structure & Dividends:** * **Paid-up Capital:** **₹9.66 Crores** (Authorised: **₹10.00 Crores**). * **Dividend Policy:** Recommended a final dividend of **₹0.80 per equity share (8%)** for FY 2024-25, maintaining consistency with the previous year. * **Warrant Conversion:** The company has a history of successful capital raises, including the conversion of **8,390,097**, **8,890,667**, and **850,326** warrants across three tranches between 2021 and 2022. --- ### **Growth Strategy & Digital Transformation** The company is executing a multi-year capital expenditure program funded through preferential equity warrants to modernize its technological backbone. * **E-commerce Acceleration:** A primary growth driver, with the digital segment recording **100% year-on-year growth** as of FY23. * **CapEx Priorities:** * **Machinery:** Revamping existing plant equipment and purchasing new high-capacity machinery. * **Infrastructure:** Civil works for major installations and marketing infrastructure development. * **Technology:** Direct investment in digital systems to enhance operational efficiency. * **Sustainability:** Transitioning toward eco-friendly packaging and energy-efficient manufacturing processes. --- ### **Risk Profile & Mitigation** Sandu Pharmaceuticals manages a complex landscape of regulatory and market-driven risks. **1. Financial & Credit Risk:** The company has observed a rise in the **Expected Credit Loss (ECL)** allowance, signaling a more cautious approach to trade receivables. * **Trade Receivables (2025):** **₹495.47 Lakhs**. * **Allowance for Doubtful Debts:** Increased from **1.65%** to **3.98%** year-on-year. **2. Regulatory & Legal Contingencies:** * **Income Tax:** Contesting a **₹2.83 Crore** demand in the **High Court of Mumbai**. * **GST:** Demands totaling **₹85.93 Lakh** are currently under appeal. * **Bio-Diversity Act:** The company is challenging the **Access Benefit Sharing (ABS)** fees, viewing them as an unnecessary tax on the Ayurvedic industry. **3. Operational Challenges:** * **Input Costs:** High inflation in raw materials exerts pressure on margins; price hikes are used but may not fully recover costs. * **Compliance:** The company is addressing **Secretarial Audit** qualifications regarding delays in financial result submissions and has received show-cause notices for minor delays in professional tax and GST payments (subject to **2.00%** interest). **4. Governance Updates:** * **Promoter Reclassification:** In September 2025, **Akshath Finvest and Properties Private Limited** (holding **5.12%**) was reclassified from 'Promoter Group' to 'Public'. * **Leadership:** Maintains a clear separation of powers between the Non-Executive Chairperson and the Managing Director, **Shri Umesh B Sandu**.